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h Abstract
To estimate whether women exposed in
utero to diethylstilbestrol (DES) report receiving more
cervical and general physical examinations compared to
unexposed women.
Materials and Methods. 1994 Diethylstilbestrol Adenosis
cohort data are used to assess the degree of recommended
compliance of cervical screenings found in 3,140 DESexposed and 826 unexposed women. Participants were
enrolled at 4 sites: Houston, Boston, Rochester, and Los
Angeles. Logistic regression modeling was used to analyze
mailed questionnaire data, which included reported frequency over the preceding 5 years (1990Y1994) of Papanicolaou smears and general physical examinations.
Objective.

Reprint requests to: Raymond H. Kaufman, MD, 6550 Fannin, Suite 900,
Houston, TX 77030. E-mail: rkaufman@tmh.tmc.edu
This study was supported by the National Cancer Institute under
contract #1-CP-21166.
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Results. Diethylstilbestrol-exposed women exceeded
the recommended frequency of Papanicolaou smear
screenings [adjusted odds ratio (aOR) = 2.15, 95% CI
(confidence interval) = 1.60Y2.88] compared to the
unexposed. This association held among those without a
history of cervical intraepithelial neoplasia (aOR = 1.88,
95% CI = 1.35Y2.62). Diethylstilbestrol-exposed women
exceeded annual recommendations for physical examinations (aOR = 2.27, 95% CI = 1.16Y4.43) among women
without a history of chronic disease when compared to
unexposed women.
Conclusions. Most DES-exposed women are receiving
cervical cancer screening at least at recommended intervals, but one third of the women are not receiving annual
Papanicolaou smear examinations. h
Key Words: diethylstilbestrol, physical examination, vaginal
smears

I

n 1971, a strong association was found between in utero
exposure to diethylstilbestrol (DES) and the development of clear cell vaginal and cervical adenocarcinoma
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[1]. Within the same year, DES use was discontinued and
no longer prescribed to maintain pregnancies [2]. Shortly
thereafter, the National Cancer Institute (NCI) awarded
contracts to 4 geographically separated institutions
(Houston, Boston, Rochester, and Los Angeles) to study
in utero DES-exposed offspring, leading to the creation of
the Diethylstilbestrol Adenosis (DESAD) Project [3, 4].
Several studies have focused on cervical and vaginal
changes in this exposed population [3, 5, 6]. This current
study examines whether DES-exposed women relative to
unexposed women are more likely to receive screening for
cervical cancer and other health problems at recommended intervals.

MATERIALS AND METHODS
Patient recruitment has previously been described [3, 4].
Briefly, DES-exposed women were recruited through
record review, physician referral, or walk-ins. The
unexposed women were recruited from available medical records and from siblings of exposed women,
matched on exposed women’s ages within 6 months
and on mothers’ ages during pregnancy within 5 years.
At the start of 1975 through 1983, both exposed and
unexposed women were examined annually and then
followed yearly with a questionnaire from 1984 to 1989
[6, 7]. Again in 1994, self-administered questionnaires
were mailed to previous DESAD participants [7]. This
study has been reviewed and approved by institutional
review boards at each participating study site.
Information describing screening behaviors was
obtained from the 1994 questionnaire, including the
number of Papanicolaou smears and the number of
general physical examinations (GPEs).
Women reported the frequency of Papanicolaou
smear screening in the past 5 years in the following
ordinal categories: none, once, 2 to 3 times, 4 to 5 times,
and more than 5 times. The Department of Health,
Education, and Welfare in 1978, the NCI in 1980, and
the American College of Obstetricians and Gynecologists in 1994 recommended annual gynecological
examinations for DES-exposed women [8Y10]. The
recommendation for Papanicolaou smear screening for
asymptomatic DES-exposed women includes not only
the cervical cytology examination but also an extensive
vaginal examination, with screening beginning at age
14, 4 years earlier than the recommendation age for
unexposed women [8, 10].
Compliance was defined as receiving 4 to 5 Papanicolaou smears in the past 5 years, whereas receiving

more than 5 was defined as exceeding recommendations. These 2 groups were compared with those with
fewer than 4 Papanicolaou smears in the past 5 years,
which was considered noncompliant. Women with
hysterectomies were excluded from the Papanicolaou
smear analysis.
For the physical examination component, compliance
was defined as having a GPEs 4 to 5 times in the past 5
years, and more than 5 was defined as exceeding
recommendations. The reference group was fewer than
4 to 5 examinations in the past 5 years. Annual
examinations were categorized as compliant, even
though periodic examinations (ranging from once to
every 4 years based on age and gender) are recommended by the American College of Physicians and the
American Medical Association [11]. However, the
reviewed literature at this time has shown that patients
expect a complete annual examination, and physicians
comply at such a request [12]. Furthermore, setting the
compliance level at a yearly examination allowed for
more straightforward comparisons across ages in the
study population.
The analysis addressed the association between DES
exposure and reported frequency of cervical cancer
screening and GPEs. Because a personal history of
cervical intraepithelial neoplasms (CIN) may result in
more frequent Papanicolaou smear screening, the
analyses were stratified to assess whether such a history
modified the association between DES exposure and
frequency of Papanicolaou smear screening. Similarly,
women with a chronic disease may be more likely to
receive more frequent physical examinations, so the
association between DES exposure and frequency of
physical examinations was conducted separately by
those who did and did not have 1 or more of the
specified chronic diseases listed in Table 1. All statistical
evaluation was performed using SPSS 11.0 statistical
software (SPSS, Inc., Chicago, IL) and EpiInfo 6.04d
(Geneva, Switzerland).
Although the parent study used a prospective cohort
design, odds ratios (OR) were chosen as the relevant
measure of association between DES exposure status
and screening frequency in the past 5 years. The
dependent outcome variables had 3 frequency levels.
Separate binary (i.e., compliant vs. noncompliant and
exceeding recommendations vs. noncompliant) logistic
regression models were used to estimate the ORs and
95% confidence intervals (CI) for each of the 2 outcome
categories that met or exceeded recommendations
compared to the reference category [13].
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Table 1. Comparison of Exposed and Unexposed Women
From the 1994 DESAD Cohort Study in Demographic and
Other Factors Associated With Gynecological Screening
and Physician Visits
DES Exposed
(n = 3,140)
No.
Age, y
25Y29
50
30Y34
354
35Y39
877
40Y44
1,296
45Y49
533
50Y55
30
Education
Less than high school
402
and postYhigh school
Junior college
724
4-Year college
1,125
Graduate school
880
Missing
9
Marital status
Single
410
Married
2,261
Widowed/divorced/separated
425
Missing
44
Site
Boston
921
Mayo
588
California
803
Baylor
828
History of CINa
Yes
672
No
2,058
Missing
410
History of an abnormal Pap smeara
Yes
1,162
No
1,588
Missing
390
History of diagnosis (ever)
b
with a sexually transmitted infection
Yes
713
No
2,427
History of chronic diseasec
Yes
890
No
2,250

DES
Unexposed
(n = 826)

%

No.

%

2
11
28
41
17
1

0
30
263
301
200
32

0
4
32
36
24
4

13

152

18

23
36
28
0.3

197
257
217
3

24
31
26
0.4

13
72
14
1

113
591
105
17

14
72
13
2

29
19
26
26

321
186
172
147

39
23
21
18

21
66
13

64
661
101

8
80
12

37
51
12

178
535
113

22
65
14

23
77

158
668

19
81

28
72

233
593

28
72

DESAD, Diethylstilbestrol Adenosis; DES, diethylstilbestrol; CIN, cervical intraepithelial
neoplasms.
a
Women with hysterectomies were excluded from this comparison (N = 415; exposed
= 322 and unexposed = 93); the Yates 2-sided p value comparing the prevalence of
hysterectomy in exposed and unexposed is 0.44.
b
Sexually transmitted infections include a diagnosis of any of the following: herpes, HIV,
chlamydia, genital warts, or syphilis.
c
Chronic disease includes a diagnosis of any of the following: lupus erythematosus,
scleroderma, rheumatoid arthritis, multiple sclerosis, chronic ulcerative colitis, regional
enteritis, insulin-dependent diabetes mellitus, thyrotoxicosis, thyroiditis, hyperthyroidism, pernicious anemia, idiopathic thrombocytopenic purpura, Addison disease, Behçet
syndrome, temporal arteritis, optic neuritis, asthma, chronic fatigue syndrome,
congenital abnormalities (spine/skeleton), or a diagnosis/treatment for depression
/mental illness.

Potential confounders for exposureYoutcome associations assessed in this study included age (in 5-year
categories), marital status (single, married, or widowed/
divorced/separated), education (high school and posthigh school , junior college, full college, and graduate

&
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school), and study site. All of these were included in the
final models as their inclusion resulted in a 10% or
greater change between the crude and adjusted estimates
for the exposureYoutcome association when comparing
the crude and adjusted associations [14]. The BreslowY
Day test for homogeneity was used to determine
whether the association between DES exposure and
screening behaviors differed by history of CIN or
chronic disease. A 2-sided p value of .25 or less was
considered evidence of effect-measure modification [13].
The Yates 2-sided p value was used to test differences in screening frequency between exposed and
unexposed women. Unconditional logistic regression
was used to estimate adjusted prevalence ORs for DES
and the categories of screening frequency levels. The
ordinal variable indicating screening frequency was
included in logistic models to assess whether DES
exposure was associated with a trend toward increased
screening frequency; the Wald 2-sided p value test was
presented [15].

RESULTS
Response rates for the 1994 questionnaire were high for
all centers: 96% of the exposed and 98% of the
unexposed women at the Boston Center, 96% of both
exposed and unexposed women at the Rochester Center,
84% of the exposed and 91% of the unexposed at the
California Center, and 89% of the exposed and 83% of
the unexposed women at the Baylor Center.
The total number of study participants who responded
to the 1994 questionnaire included 3,140 exposed women
and 826 unexposed women, 98% of whom were
Caucasian. Among the exposed women who responded
to the 1994 questionnaire, 46% were originally recruited
into the cohort through record review, 33% through
physician referral, and 21% were walk-ins. In the
unexposed population, 75% were recruited through
record review and 25% were siblings of exposed women.
Diethylstilbestrol-exposed women were similar to
unexposed women on study variables with the following
exceptions (Table 1): unexposed women were older
(unexposed mean age = 42 years, and DES-exposed mean
age = 40 years; Yates 2-sided p G .0001), whereas DESexposed women were more highly educated (p G .0001)
than unexposed women (those whose education did
not exceed high school, including nongraduates, and
those with postYhigh school vocational training were
compared to those with the higher levels of junior college
through graduate school). There was no significant
difference between exposed and unexposed women
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Table 2. Adjusted Odds Ratios and 95% Confidence Interval for Pap Smear Visits in the Past 5 Years (1990Y1994) for
DESAD Exposed and Unexposed Women With Intact Uteri
DES Exposed
(n = 2,818)
No.
No. of Pap smear visits in past 5 yearsa
Missingd
None
Once
2Y3 timese
4Y5 timesf
95 timesg
Reported history of CIN (n = 732)

7
60
167
601
1,381
602

%

No.

%

Adjusted ORb

0.2
2
6
21
49
21

8
17
52
186
393
77

1
2
7
25
54
11

1.00
1.05
2.15

REF
0.87Y1.27
1.60Y2.88

G0.001

1.00
0.48
0.75

REF
0.22Y1.02
0.32Y1.77

0.33

1.00
1.05
1.88

REF
0.86Y1.29
1.35Y2.62

0.002

DES exposed
(n = 668)
None
Once
2Y3 timese
4Y5 timesf
95 timesg
Reported no history of CIN (n = 2,709)

7
31
102
296
232

1
5
15
44
35

DES exposed
(n = 2,056)
None
Once
2Y3 timese
4Y5 timesf
95 timesg

52
133
485
1,040
346

DES
Unexposed
(n = 733)

3
7
24
51
17

95% CI

p for trendc

DES
unexposed
(n = 64)
0
1
9
36
18

0
2
14
56
28

DES
unexposed
(n = 653)
16
51
175
353
58

3
8
27
54
9

DESAD, Diethylstilbestrol Adenosis; DES, diethylstilbestrol; OR, odds ratio; CI, confidence interval; CIN, cervical intraepithelial neoplasia; REF, reference group.
a
Women with previous hysterectomies were removed from the analysis (N = 415; exposed = 322, unexposed = 93).
b
Adjusted for age (continuous variable), education, marital status, and study site.
c
The p value (2-sided) for trend included all 5 outcome frequency categories; none of the frequency categories were combined for the trend test.
d
Missing values indicate a nonresponse to the question regarding number of Pap smear visits in the past 5 years.
e
Categories (none, once, and 2Y3 times) were combined to form the reference category.
f
The category 4Y5 times was compared with the reference group and defined as compliant for annual Pap smear screening.
g
The category more than 5 times was compared with the reference group and defined as exceeding recommendations for annual Pap smear screening.

regarding marital status (p = .98). However, DES-exposed
women were more likely to report having a history of CIN
(p G .0001) than unexposed women, history of an
abnormal Papanicolaou smear (p G .0001), and a
diagnosis of a sexually transmitted infection (e.g., herpes,
HIV, chlamydia, genital warts, or syphilis) (p = .03). There
was no significant difference between exposed and
unexposed women regarding a history of chronic disease
(p = .97), BBD (p = .94), and hysterectomies (p = .44).
Table 2 presents the association between DES exposure and Papanicolaou smear screening frequency.
Diethylstilbestrol-exposed women were more likely to
exceed recommendations for annual Papanicolaou smear
screening [adjusted odds ratio (aOR) = 2.15, 95% CI =
1.60Y2.88]. Among women without a reported history of
CIN, DES-exposed women were more likely than
unexposed women to exceed recommendations for

Papanicolaou smears (aOR = 1.88, 95% CI =
1.35Y2.62; p value for trend = .002), whereas among
women with a history of CIN, this was not observed.
Among all women, DES exposure was not associated
with receiving more general physical visits. However,
among women with no history of chronic disease, DES
exposure was positively associated with reporting more
than 5 visits in the past 5 years (aOR = 2.27, 95% CI =
1.16Y4.43; p value for trend = .07) (Table 3), yet DES
exposure was not associated with an increased frequency of GPEs among women with a reported history
of a chronic disease.
The analysis was also repeated, removing the women
who had never had a screening examination within the
past 5 years from the noncompliant group, under the
assumption that these women maybe fundamentally
different than women who have had at least 1 screening
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Table 3. Adjusted ORs and 95% Confidence Intervals for General Physical Examinations in the Past 5 Years (1990Y1994)
in DESAD Exposed and Unexposed Women
DES Exposed
(n = 3,140)

No. of physical exams in the past 5 years
Missingc
None
Once
2Y3 timesd
4Y5 timese
95 timesf
Reported history of chronic diseaseg (n = 1,105)

No.

%

No.

%

Adjusted ORa

64
491
780
1,005
641
159

2
16
25
32
20
5

23
113
211
266
183
30

3
14
26
32
22
4

1.00
0.96
1.30

REF
0.79Y1.17
0.87Y1.96

0.58

1.00
1.03
0.81

REF
0.72Y1.46
0.47Y1.40

0.81

1.00
0.93
2.27

REF
0.73Y1.17
1.16Y4.43

0.07

DES exposed
(n = 878)
None
Once
2Y3 timesd
4Y5 timese
95 timesf
Reported no history of chronic diseaseg (n = 2,764)

97
184
310
224
63

11
21
35
25
7

DES exposed
(n = 2,198)
None
Once
2Y3 timesd
4Y5 timese
95 timesf

DES
Unexposed
(n = 826)

394
596
695
417
96

18
27
31
19
4

95% CI

p for trendb

DES
unexposed
(n = 227)
27
43
78
59
20

12
19
34
25
9

DES
unexposed
(n = 576)
86
168
188
124
10

15
28
32
21
2

DESAD, Diethylstilbestrol Adenosis; DES, diethylstilbestrol; OR, odds ratio; CI, confidence interval; REF, reference group.
a
Adjusted for age (continuous variable), education, marital status, and study site.
b
The p value (2 sided) for trend included all 5 outcome frequency categories; none of the frequency categories were combined for the trend test.
c
Missing values indicate a nonresponse to the question regarding number of general physical examinations in the past 5 years.
d
Categories (none, once and 2Y3 times) were combined to form the reference category.
e
The category 4Y5 times was compared to the reference group and defined as compliant for annual, general physical examinations.
f
The category more than 5 times was compared to the reference group and defined as exceeding recommendations for annual, general physical examinations.
g
Chronic disease includes a diagnosis of any of the following: lupus erythematosus, scleroderma, rheumatoid arthritis, multiple sclerosis, chronic ulcerative colitis, regional enteritis,
insulin-dependent diabetes mellitus, thyrotoxicosis, thyroiditis, hyperthyroidism, pernicious anemia, idiopathic thrombocytopenic purpura, Addison’s Disease, Behçet’s Syndrome,
temporal arteritis, optic neuritis, asthma, chronic fatigue syndrome, congenital abnormalities (spine/skeleton), or a diagnosis/treatment for depression /mental illness.

examination. This comparison analysis was no different
from the original crude and adjusted ORs analysis
previously discussed.

DISCUSSION
The results of this study showed that the behavior of
women who knew they were exposed to DES in utero
but had never had a report of CIN was associated
with more than the recommended number of Papanicolaou smear screenings. Diethylstilbestrol exposure was
also associated with more than annual physical examinations among those without a history of a chronic
disease. It appears that women exposed to DES are
aware of their increased risk of such conditions, and this
possibly influences their increased rate of screening
procedures.

A strength of the DESAD study was its efforts to
address the problem of selection bias. To reduce
selection bias that may result when study respondents
disproportionately include volunteers compared with a
more random population-based sample, medical records
were linked with live birth data for exposed and
unexposed women. Exposed women were then invited
to participate in the study [4]. This strategy should have
minimized a selection bias that can occur when more
health-conscience volunteers are participating in the
study, resulting in an OR moving away from the null.
Another strength of the DESAD study was its efforts to
reduce loss-to-follow-up. All study sites had an interview response rate of at least 80% from the study
inception, and some cohorts exceeded a 90% response
rate, which is rare in any large study continuing over a
period of decades.
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Study limitations included the potential for misclassification of the reported frequencies of cervical and
physical examinations. Although the DESAD study
had an established diagnosis verification system, in
the data used for this analysis, screening examinations
and health conditions were not verified by pathology
or medical reports. Therefore, this study relied solely
on self-report of screening and previous health conditions that were examined as potential effect-measure
modifiers.
According to previous reports, women tend to overreport the frequency of cervical cancer screening
[16Y19]. There is no evidence to suggest that DESexposed women were more likely than unexposed
women to overreport the frequency of screening examinations. However, previous data showed that DESexposed women were more likely than unexposed
women to misreport their diagnoses [6]. If DES-exposed
women overstated screening frequency to a greater
extent than unexposed women, this would bias the OR
away from the null; however, if such differential
misclassification were the case, we would expect to
observe positive associations for both cervical screening
and GPEs, but this did not occur.
The lack of insurance information in this study
may result in confounding by health-care access. If
DES-exposed women were more likely than unexposed women to have insurance and therefore receive
more frequent screening, then insurance status, rather
than DES exposure, would be the factor that led
to more frequent screening. Potential confounding
could only be operating if insurance status led to
more frequent screening and was more common in
DES-exposed women. We attempted to address this
issue of potential confounding by adjusting for education and marital status, which are highly correlated
with receiving preventive care [20, 21] and being
insured [22].
A total of 29% of DES-exposed women were not
receiving annual Papanicolaou smear examinations
(e2Y3 examinations in the past 5 years) as recommended
by the Department of Health, Education, and Welfare;
NCI; and the American College of Obstetricians and
Gynecologists [8Y10]. Among the exposed women who
did not meet these recommendations, 21% reported a
history of CIN and 34% reported no history of CIN.
These percentages are of concern because DES-exposed
women are recommended to have annual Papanicolaou
smear examinations [8Y10]. Future efforts should be
focused on prevention by encouraging this exposed

population to comply with their recommended annual
cervical and vaginal screenings. Furthermore, periodic
reminders from the offices of their attending gynecologists may also increase the number of their annual
visits.
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